KDIGONephrology2024New Guideline

KDIGO Clinical Practice Guideline for CKD Evaluation, Management and Treatment 2024

Published by Kidney Disease: Improving Global Outcomes · 94 pages · Class I–II

Class ISGLT2i

2021 CKD-EPIeGFR equation

Class IIaFinerenone

Summary

Free preview

Comprehensive update to KDIGO CKD guidelines. SGLT2 inhibitors now Class I for CKD with or without diabetes to slow progression. Finerenone recommended in diabetic CKD. Updated GFR equations (2021 CKD-EPI without race coefficient) and revised staging criteria for cardiorenal syndrome.

CKDSGLT2iFinerenoneeGFRCardiorenal syndromeDiabetic nephropathy

Key Recommendations

Evidence Grading & Drug Doses

What's New vs Previous Version

Implementation & Clinical Pearls

Full guideline access requires an account

Create a free Prognia account to read the complete guideline — including all recommendations, evidence tables, drug dosing, and clinical pearls.

Full guideline text with all recommendations

Evidence grades (Class I/II/III, Level A/B/C)

AI-generated summary and clinical pearls

Auto-logged as CPD/CME activity

Create Free Account — Instant Access Sign In

Free plan includes 10 guideline reads per day · No credit card required

Loading your page…